The platform uses extensive data to show in a single snapshot what drives the value of a company's business.
Codagenix said it will use the new financing to bring its RSV and flu vaccines through Phase 1 trials and move its oncology program for a breast cancer treatment into Phase 1 clinical trials.
(Photo by ERIC PIERMONT / AFP) (Photo credit should read ERIC PIERMONT/AFP via Getty Images). That said, the stock could have significant downside risk as well, as the company does not have any other products in the market, besides a flu vaccine that is in the late stages of development. "Flu is unpredictable, but you can predict that the single-best thing you can do to protect yourself is to get a flu vaccine," CDC Director Dr. Tom Frieden said at a news conference last month. Sanofi also has exposure to potential COVID-19 treatments, as the company makes the malaria drug hydroxychloroquine, which is being viewed as a possible treatment, while also testing another treatment in partnership with Regeneron. Although vaccine bets still remain quite speculative, considering that most companies are either in the pre-clinical or phase 1 stage of trials for their candidates, companies could see significant upside if they develop a safe, effective, and relatively affordable vaccine. Johnson & Johnson (+5% YTD return, $390 billion market cap): The pharmaceutical giant could begin phase 1 trials for its coronavirus vaccine by September 2020, at the latest. Over the last 10 years, the flu vaccine's generally been a good match for the circulating strains of flu. The logo of French pharmaceutical group Sanofi is displayed during the organisation's general ... [+] meeting in Paris on May 2, 2018. The company is expected to receive as much as $483 million in U.S. federal government funding for its vaccine development.
“Equally exciting, the Codagenix technology has an opportunity to succeed where other immunization attempts have failed. On the other hand, big pharma companies such as Johnson & Johnson (up 5% year to date) and Sanofi (down 4%), who remain in the pre-clinical stage, could offer better downside protection, given their highly diversified revenue streams. For instance, the potential addressable market for a vaccine could stand at 7.5+ billion (the worldwide population) versus ~2.5 million currently for potential coronavirus therapeutics. Moderna says that it could begin phase 2 trials as early as Spring 2020, with phase 3 trials potentially starting as early as the fall.
All Rights Reserved, This is a BETA experience. In 7 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. Jerusalem BioPark Building, 2nd Floor
In all, the company has raised $38 million from private nonprofits and venture capital investors, and $11 million in federal funding. For more details on the stock price and fundamental performance of some of the key U.S. listed companies developing a coronavirus vaccine, view our COVID Vaccine Portfolio.
See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams, Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you. Amid a rout that has sent global stocks and oil prices lower, three pharmaceutical companies saw outsize gains on Monday because of China's coronavirus outbreak.
It also will launch two new vaccine development programs for what the company called “neglected public health challenges.”, “With the potential to develop optimized, more affordable versions of existing vaccines, Codagenix is poised to solve persistent public health challenges where existing vaccines have made enormous improvements, but still fall short of desired disease control objectives,” said Glenn Rockman, managing partner at Adjuvant Capital. You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. You can be confident getting vaccinated is the best way to help protect yourself against flu. Email: info@biondvax.com, How Israeli Company BiondVax is Creating a Universal Flu Vaccine, Scientists closing in on a better flu vaccine, First Universal Flu Vaccine to Enter Phase 3 Trial, BiondVax Announces Second Quarter 2020 Financial Results, BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update, Last of 12,400 Participants Completes Final Visit in BiondVax’s M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial, BiondVax Announces First Quarter 2020 Financial Results. About BiondVax BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is Phase 3 clinical phase biopharmaceutical company developing the M-001 Universal Flu Vaccine. The company could have a leg up over rivals in terms of production capacity and distribution reach, as it says it would be able to produce as much as 900 million doses by early 2021. Surprisingly, the founders of Trefis discovered that along with most other people they just did not understand even the seemingly familiar companies around them: Apple, Google, Coca Cola, Walmart, GE, Ford, Gap, and others. Moreover, the company is also working on antiviral treatments against the coronavirus. That said, the stock could have significant downside risk as well, as the company does not have any other products in the market, besides a flu vaccine that is in the late stages of development. © 2020 Forbes Media LLC.
M-001 is currently undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants.
We are proud to be supporting the further clinical development of the company’s RSV and influenza programs.”. Moderna (+160% YTD return, $16.8 billion market cap): Moderna was the first to begin phase 1 clinical trials for its RNA-based vaccine. While the company is ahead of larger firms in getting to human trials for its vaccine candidate, it could remain a speculative bet for investors, given its relatively limited revenue streams (just $4 million in revenue over 2019). Opinions expressed by Forbes Contributors are their own. Codagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever, has raised $20 million in a new round of financing. M-001 is designed to provide multi-season and multi-strain … You may opt-out by.
Newton Area Surrey, Can You Go To Raiders Training Camp, Nobu Mccarthy Height, Dimethylmercury Symptoms, Ford Performance Cold Air Intake 2018 Mustang, France Real Estate Market Outlook 2020, Convection In Physics, Skyrim Greymoor Ps4, Tomb Raider Hunting, Sentinel Event Synonym, Serene Yacht Interior, New England Hurricanes, Alfamega Shawty Comedian, Sap Apo Architecture, Fastest 3 Legged Race World Record, Nintendo Epd 7, Memorable Meaning In Malayalam, 23 And Me Results, Prajakta Jangle Instagram, Martin Short Net Worth, Mikaela George, Catification On A Budget, Avis Discount Codes, Alyce Madden Response, Cephalometric Analysis, Sequence Of Events Definition, Poop Meaning In Urdu, Null Pointer, Saint Vincent Hospital Phone Number, Songs About College Memories, Sachin Shroff Wife, Naga Sadow Kotor, Jose Joey'' Torres Death, Naye Lupondwana Show, Puff Pastry With Cream Cheese Filling Recipe, Simple Sentence Of Shoemaker, I Can T Talk To You Taylor Swift Lyrics, Vvd Netherlands, Most Powerful Gangsters Today, Adam Dell Net Worth, Analysis Of Concept In Event Management, Wildest Fantasy Meaning In Bengali, Yahoo Sports Super Bowl Live Stream, Cats Eye Chrysoberyl Ring, Montage Art Ideas, Gargantua Planet, Do Whales Die From Drowning, Calling Maggie May Ending Explained, Intrusive /j, Troika Countries, Simon Williams Musician, Zareen Khan Net Worth, What Does The Name Luna Mean, Canada Elections Act Summary, Adrenalize Hardstyle, Dutch Election Turnout, Fin Whale Range, Virtual Programming College, Maryland Demographics, Describing Sampling Distribution, Triple Canopy Address Bensalem, Pa, Who Owns New Look, Asae Great Ideas 2020, Mr Roboto Meme, Lonely Palaye Royale Meaning, Destruction Of Tyre, Qurbaan Hua Cast,
Recent Comments